Zacks Research Upgrades Spero Therapeutics (NASDAQ:SPRO) to Hold

Spero Therapeutics (NASDAQ:SPRO) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued on Monday, Zacks reports.

Several other equities research analysts also recently weighed in on SPRO. Compass Point raised Spero Therapeutics to a “neutral” rating in a report on Monday. Weiss Ratings raised shares of Spero Therapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, August 12th. Finally, HC Wainwright upped their price target on shares of Spero Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Spero Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Stock Performance

Spero Therapeutics stock opened at $1.13 on Monday. The company has a market capitalization of $65.81 million, a P/E ratio of 10.27 and a beta of 1.49. Spero Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.08. The stock has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $2.10.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. As a group, analysts forecast that Spero Therapeutics will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors have recently added to or reduced their stakes in SPRO. Alphabet Inc. acquired a new stake in Spero Therapeutics in the second quarter valued at about $1,967,000. BlackRock Inc. acquired a new position in Spero Therapeutics during the 2nd quarter worth approximately $1,314,000. GSA Capital Partners LLP acquired a new position in Spero Therapeutics during the 2nd quarter worth approximately $632,000. Intrepid Family Office LLC raised its stake in shares of Spero Therapeutics by 50.0% during the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock worth $384,000 after buying an additional 55,000 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Spero Therapeutics during the 2nd quarter worth approximately $55,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.